Literature DB >> 16038023

Treatment of uncomplicated reflux disease.

Joachim Labenz1, Peter Malfertheiner.   

Abstract

Uncomplicated reflux disease comprises the non-erosive reflux disease (NERD) and erosive reflux disease (ERD). The objectives of treatment are the adequate control of symptoms with restoration of quality of life, healing of lesions and prevention of relapse. Treatment of NERD consists in the administration of proton pump inhibitors (PPI) for 2-4 wk, although patients with NERD show an overall poorer response to PPI treatment than patients with ERD owing to the fact that patients with NERD do not form a pathophysiologically homogenous group. For long-term management on-demand treatment with a PPI is probably the best option. In patients with ERD, therapy with a standard dose PPI for 4-8 wk is always recommended. Long-term treatment of ERD is applied either intermittently or as continuous maintenance treatment with an attempt to reduce the daily dosage of the PPI (step-down principle). In selected patients requiring long-term PPI treatment, antireflux surgery is an alternative option. In patients with troublesome reflux symptoms and without alarming features empirical PPI therapy is another option for initial management. Therapy should be withdrawn after initial success. In the case of relapse, the long-term care depends on a careful risk assessment and the response to PPI therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16038023      PMCID: PMC4434651          DOI: 10.3748/wjg.v11.i28.4291

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  80 in total

1.  Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.

Authors:  P Malfertheiner; T Lind; S Willich; M Vieth; D Jaspersen; J Labenz; W Meyer-Sabellek; O Junghard; M Stolte
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.

Authors:  John M Inadomi; Lisa McIntyre; Latoya Bernard; A Mark Fendrick
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

3.  Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus".

Authors:  R G Watson; T C Tham; B T Johnston; N I McDougall
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

4.  Non-erosive reflux disease (NERD)--acid reflux and symptom patterns.

Authors:  S D Martinez; I B Malagon; H S Garewal; H Cui; R Fass
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

5.  On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial.

Authors:  T Lind; T Havelund; L Lundell; H Glise; K Lauritsen; S A Pedersen; O Anker-Hansen; A Stubberöd; G Eriksson; R Carlsson; O Junghard
Journal:  Aliment Pharmacol Ther       Date:  1999-07       Impact factor: 8.171

Review 6.  Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs.

Authors:  J Dent; D Armstrong; B Delaney; P Moayyedi; N J Talley; N Vakil
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.

Authors:  H H Tsai; R Chapman; A Shepherd; D McKeith; M Anderson; D Vearer; S Duggan; J P Rosen
Journal:  Aliment Pharmacol Ther       Date:  2004-09-15       Impact factor: 8.171

8.  Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

Authors:  T L Venables; R D Newland; A C Patel; J Hole; C Wilcock; M L Turbitt
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

9.  Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.

Authors:  Tina M Ours; W Keith Fackler; Joel E Richter; Michael F Vaezi
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

10.  A comparison of five maintenance therapies for reflux esophagitis.

Authors:  S Vigneri; R Termini; G Leandro; S Badalamenti; M Pantalena; V Savarino; F Di Mario; G Battaglia; G S Mela; A Pilotto
Journal:  N Engl J Med       Date:  1995-10-26       Impact factor: 91.245

View more
  19 in total

1.  Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease.

Authors:  Naomi Uemura; Hideto Inokuchi; Hiroshi Serizawa; Toshiharu Chikama; Masao Yamauchi; Tomomi Tsuru; Toru Umezu; Toshiro Urata; Nobuo Yurino; Satoshi Tanabe; Tomoharu Yoshida; Susumu Kawamura; Atsushi Murakami; Munemitsu Yamamoto; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

Review 2.  LINX® magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis.

Authors:  Daniel Skubleny; Noah J Switzer; Jerry Dang; Richdeep S Gill; Xinzhe Shi; Christopher de Gara; Daniel W Birch; Clarence Wong; Matthew M Hutter; Shahzeer Karmali
Journal:  Surg Endosc       Date:  2016-12-15       Impact factor: 4.584

3.  The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders.

Authors:  Muhammad Ali Khan; Colin W Howden
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

4.  Presence of minimal change esophagitis closely correlates with pathological conditions in the stomach.

Authors:  Tomomitsu Tahara; Tomoyuki Shibata; Masakatsu Nakamura; Joh Yonemura; Masaaki Okubo; Daisuke Yoshioka; Yoshio Kamiya; Tomiyasu Arisawa; Ichiro Hirata
Journal:  Dig Dis Sci       Date:  2011-11-17       Impact factor: 3.199

Review 5.  Medical Treatment of Gastroesophageal Reflux Disease.

Authors:  Daniel A Kroch; Ryan D Madanick
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

Review 6.  Experimental human pain models in gastro-esophageal reflux disease and unexplained chest pain.

Authors:  Asbjørn Mohr Drewes; Lars Arendt-Nielsen; Peter Funch-Jensen; Hans Gregersen
Journal:  World J Gastroenterol       Date:  2006-05-14       Impact factor: 5.742

7.  Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: con.

Authors:  Lucía C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

8.  Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus.

Authors:  Zdenek Kala; Jiří Dolina; Filip Marek; Lydie Izakovicova Holla
Journal:  J Hum Genet       Date:  2007-05-03       Impact factor: 3.172

9.  Severe adverse reactions caused by omeprazole: A case report.

Authors:  Meiling Yu; Jianghua Qian; Daohua Guo; Li Li; Xiaolin Liu
Journal:  Exp Ther Med       Date:  2016-06-08       Impact factor: 2.447

10.  Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Rachel Rosen; Yvan Vandenplas; Maartje Singendonk; Michael Cabana; Carlo DiLorenzo; Frederic Gottrand; Sandeep Gupta; Miranda Langendam; Annamaria Staiano; Nikhil Thapar; Neelesh Tipnis; Merit Tabbers
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-03       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.